No Data
No Data
Viatris Hosts R&D Event Focusing on Its Collaboration With Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of Its Pipeline
PITTSBURGH, March 27, 2024 /PRNewswire/ -- At a meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will outline how it is continuing to evolve its
Insights Into the Generic Drugs Market in Canada, 2024-2032, Featuring Apotex, Mylan Pharmaceuticals, Pharmascience, Sandoz, Sun Pharma Industries, and Teva Pharmaceutical Industries
Idorsia and Viatris Successfully Close the Transaction for the Global Research and Development Collaboration
Viatris(VTRS.US) Officer Sells US$3.02 Million in Common Stocks
$Viatris(VTRS.US)$ Officer Mauro Anthony sold 250K shares of Common Stocks on Mar 13, 2024 at an average price of $12.0948 for a total value of $3.02 million.Source: Announcement What is statement of
Looking Into Viatris's Recent Short Interest
Viatris's (NYSE:VTRS) short percent of float has risen 9.15% since its last report. The company recently reported that it has 33.72 million shares sold short, which is 3.22% of all regular shares that
Secure, Not Stretched, Dividends Stocks of the Russell 1000 Quintile 2 - BofA
No Data
Ape Power : 🔥 KEN GRIFFIN COMMITTED FRAUD LIVE ON AIR! 🔴 - AMC Stock Short Squeeze Update